Lutetium-177 PSMA Therapy for Prostate Cancer

Lutetium-177 DOTATATE therapy for neuroendocrine tumor

What is Lutetium-177 PSMA Therapy?

Lutetium-177 PSMA (psamma) therapy is a promising new approach for treating advanced prostate cancer. It utilizes a targeted radiation treatment strategy to deliver radiation directly to cancer cells, minimizing damage to healthy tissues.

Who is it For?

Lutetium-177 PSMA therapy is typically recommended for men with:

How Does it Works?

The Next Generation Technology is Here at Kiran PET CT - GE-DISCOVERY IQ GEN 2

Discovery IQ Gen 2 is the smartest choice for ensuring better outcomes through true discovery

Why Choose Us

Discover the future of healthcare at Kiran Nuclear Medicine and PET CT Center. Our pioneering theranostics approach not only diagnoses but also tailors treatment plans specific to your needs, ensuring precise and effective care. Experience the power of personalized medicine with us.
Radioactive iodine therapy

Pioneering Theranostics

At Kiran Nuclear Medicine and PET CT Center, we're leading the way in theranostics, integrating advanced diagnostics with personalized treatment plans.

Radioactive iodine therapy

Precision and Effectiveness

Our commitment to theranostics means that you receive precise diagnoses and targeted therapies, leading to more effective treatment outcomes. We leverage cutting-edge technology and expertise to deliver the highest standard of care.

Radioactive iodine therapy

Personalized Medicine

We prioritize your individual health needs, providing customized treatment plans that consider your medical history, preferences, and treatment goals.

Meet Our Doctors

Dr Kiran Kumar JK

Dr Kiran Kumar JK

Founder and Director MBBS, MD(PGIMER)
Dr Manoj Devanathan

Dr Manoj Devanathan

Medical Director MBBS, MD(JIPMER)
Dr Abhiram GA

Dr Abhiram GA


Frequently asked questions

What is Lutetium-177 PSMA Therapy?

Lutetium-177 PSMA Therapy is a targeted radionuclide therapy used in the treatment of metastatic castration-resistant prostate cancer (mCRPC). It involves the use of a radioactive isotope, Lutetium-177, coupled with a PSMA (Prostate-Specific Membrane Antigen) targeting molecule. This combination allows for the selective delivery of radiation to prostate cancer cells that express PSMA.

How does Lutetium-177 PSMA Therapy work?

PSMA is a protein that is overexpressed on the surface of prostate cancer cells. Lutetium-177, a beta-emitting radionuclide, is attached to a molecule that specifically binds to PSMA. When injected into the patient’s bloodstream, the PSMA-targeted molecule seeks out and binds to prostate cancer cells wherever they may be in the body. The radiation emitted by Lutetium-177 then damages the cancer cells, leading to their destruction.

Who is a candidate for Lutetium-177 PSMA Therapy?

Lutetium-177 PSMA Therapy is typically recommended for patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed despite standard treatments such as hormone therapy and chemotherapy. It may also be considered for patients who are not candidates for other treatments or who have experienced disease progression after previous therapies.

Is Lutetium-177 PSMA Therapy safe?

Lutetium-177 PSMA Therapy is generally considered safe when administered by trained healthcare professionals in specialized nuclear medicine facilities. However, like any medical treatment, there are potential side effects and risks associated with the therapy, including bone marrow suppression, kidney damage, and radiation exposure to other tissues. Patients will be closely monitored during and after treatment to manage any adverse effects.

What should I expect during Lutetium-177 PSMA Therapy?

Before undergoing Lutetium-177 PSMA Therapy, patients may undergo imaging studies such as PET/CT scans with PSMA tracers to assess the extent of disease and PSMA expression. The therapy itself involves the intravenous administration of Lutetium-177 PSMA, typically as a series of treatments spaced several weeks apart. Patients may experience side effects such as fatigue, nausea, and dry mouth, which are usually temporary and manageable.

What are the expected outcomes of Lutetium-177 PSMA Therapy?

Lutetium-177 PSMA Therapy has shown promising results in clinical studies, with many patients experiencing a reduction in tumor size, relief of symptoms, and improved quality of life. However, individual responses to the therapy can vary, and not all patients may derive the same benefit. The therapy may also be used in combination with other treatments as part of a comprehensive management plan for metastatic prostate cancer.

Book Your Scan Now

Book Your Scan Now

Banshankari Location

Indira Nagar Location

For Immediate Assistance

Download Catalogue Now

Book Now & Get 20% off On First Visit